Evidence map›Paper›PMID 24963354›Full record

ArticleJournal of Cancer2014

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan.

Hiroki Nishikawa, Haruhiko Takeda, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Yukio Osaki, Namiki Izumi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Hiroki Nishikawa1. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital;
Haruhiko Takeda1. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital;
Kaoru Tsuchiya2. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital;
Kouji Joko3. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital;
Chikara Ogawa4. Department of Gastroenterology, Takamatsu Red Cross Hospital;
Hiroyoshi Taniguchi5. Department of Gastroenterology, Japanese Red Cross Medical Center;
Etsuro Orito6. Department of Gastroenterology and Hepatology Nagoya Daini Red Cross Hospital;
Yasushi Uchida7. Department of Gastroenterology, Matsue Red Cross Hospital.
Yukio Osaki1. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital;
Namiki Izumi2. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital;
Japanese Red Cross Liver Study Group
Osaka Red Cross Hospital · JPMusashino Red Cross Hospital · JPJapanese Red Cross Medical Center · JPMatsuyama Red Cross Hospital · JPRed Cross Hospital · GRTakamatsu Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsWe aimed to compare clinical outcomes and safety after sorafenib therapy between patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C hepatocellular carcinoma (HCC) aged ≥75 years (aged group, n=179) and those with BCLC stage B or C HCC aged <75 years (control group, n=279). PATIENTS AND

methodsWe compared overall survival (OS), progression free survival (PFS), best treatment response and sorafenib related serious adverse events (SAEs) of grade 3 or more in the two groups. Furthermore, for reducing the selection bias, we compared clinical outcome of these two groups using propensity score matching analysis.

resultsThe median OS and PFS intervals were 9.7 and 3.8 months in the aged group and 8.2 and 3.3 months in the control group (P=0.641 for OS and P=0.068 for PFS). Disease control rates were 49.2% (88/179) in the aged group and 49.1% (137/279) in the control group (P>0.999). Objective response rates were 15.1% (27/179) in the aged group and 14.3% (40/279) in the control group (P=0.892). Treatment related SAEs of grade 3 or more were observed in 51 patients (28.5%) in the aged group and in 69 patients (24.7%) in the control group (P=0.385). In the propensity score matched cohort (132 pairs), no significant difference in the two groups was observed in terms of OS (P=0.898) and PFS (P=0.407).

conclusionIn BCLC stage B or C HCC patients treated with sorafenib, life expectancy, disease progression, treatment efficacy and SAEs are unaffected by age over 75 years.

Indexed as

Aged patientsClinical outcomeHepatocellular carcinomaSafety.Sorafenib

Identifiers

PMID24963354
PMCPMC4067509
OpenAlexW2115457093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.